Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.
In a controlled trial burn patients at risk of Pseudomonas aeruginosa septicaemia were passively immunised with an immunoglobulin prepared from plasma from healthy human volunteers vaccinated with a polyvalent pseudomonas vaccine; passively immunised and vaccinated; or only vaccinated. In children the mortality was lowest in those passively immunised (0%, 0/18); it was 21% (9/42) in controls. In adults the mortality rate of those receiving immunoglobulin or vaccine was 10% (3/30) or 8.3% (5/60), respectively, compared with 36% (22/61) in controls. Combined vaccine and immunoglobulin treatment gave rather less protection (mortality 13.6%, 3/22) than vaccine alone. Pseudomonas infection of burns was less common in patients who received immunoglobulin than in vaccinated or control patients.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002056:Burns / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000627:therapeutic use*; D007223:Infant; D008875:Middle Aged; D011549:Pseudomonas / Q000276:immunology*; D011552:Pseudomonas Infections / Q000401:mortality / Q000517:prevention & control*; D012306:Risk; D018805:Sepsis / Q000517:prevention & control; D014611:Vaccination; D014946:Wound Infection / Q000517:prevention & control
D001428:Bacterial Vaccines; D007136:Immunoglobulins